Synthesize preclinical and clinical insights: Understand the intersection of preclinical data and clinical trial outcomes in designing effective combined modality trials. They should also be able to address specific cancer types and treatments: Focus on the unique challenges and opportunities in brain tumors, brain metastases, sarcomas, gastrointestinal malignancies and hepatocellular carcinoma.
Enhance collaboration and standardization: Emphasize the importance of collaborative efforts, standardization in preclinical studies and innovative clinical trial designs. They should also be able to explore NCIs role and expectations: Gain insight into the NCIs perspective on approving combined modality trials, focusing on their specific interest groups.
